Jazz Pharmaceuticals
JAZZ
231.19
-0.20
-0.09%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
231.19
-0.20
-0.09%
Live - 5344 symbols - heartbeat 109s ago
· 2026-10-08 04:15
Pre-market
229.85
-0.58%
After-hours
231.19
0.00%
Overnight
231.85
+0.29%
- Market cap
- 15.01B
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on JAZZ?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.01, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.88% YoY
Margins
- Gross margin
- 88.21%
- Operating margin
- 12.13%
- Net margin
- -8.35%
Key ratios & quality
- Enterprise valuei
- 17.94B
- Altman Z-Scorei
- 2.01
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89B | 2.16B | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B |
| Gross profit | 1.77B | 2.03B | 2.21B | 2.65B | 3.12B | 3.40B | 3.62B | 3.76B |
| Selling & admin expenses | 683.53M | 736.94M | 854.23M | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B |
| Research & development | 226.62M | 299.73M | 335.38M | 505.75M | 590.45M | 849.66M | 884.00M | 782.74M |
| Operating profit | 657.73M | 642.35M | 765.46M | 170.28M | 512.27M | 597.58M | 726.63M | 517.62M |
| Pretax profit | 529.46M | 454.30M | 275.10M | -112.84M | -372.78M | 297.93M | 470.35M | -627.86M |
| Tax | 80.16M | -73.15M | 33.52M | 216.12M | -158.65M | -119.91M | -91.43M | -272.44M |
| Net profit | 447.10M | 523.37M | 238.62M | -329.67M | -224.06M | 414.83M | 560.12M | -356.15M |
| Basic EPS | 7 | 9 | 4 | -6 | -4 | 7 | 9 | -6 |
| Diluted EPS | 7.30 | 9.09 | 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 897.80M | 1.05B | 1.13B | 1.20B | 1.07B | 1.21B |
| Gross profit | 793.20M | 929.40M | 997.23M | 1.04B | 934.80M | 1.09B |
| Selling & admin expenses | 514.00M | 358.40M | 530.65M | 406.21M | 352.70M | 389.20M |
| Research & development | 180.70M | 189.90M | 198.20M | 213.91M | 196.00M | 207.50M |
| Operating profit | -55.90M | 219.00M | 100.01M | 254.54M | 336.60M | 325.20M |
| Pretax profit | -109.80M | -735.60M | 9.04M | 208.47M | 299.20M | 211.00M |
| Tax | -17.80M | -17.20M | -242.42M | 4.96M | 6.10M | 18.10M |
| Net profit | -92.50M | -718.50M | 251.41M | 203.45M | 293.10M | 192.80M |
| Basic EPS | -2 | -12 | 4 | 3 | 5 | 3 |
| Diluted EPS | -1.52 | -11.74 | 4.08 | 3.21 | 4.43 | 2.78 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.23B | 1.63B | 2.84B | 2.61B | 2.61B | 3.44B | 4.63B | 4.17B |
| Cash & ST investments | 824.62M | 1.08B | 2.13B | 591.45M | 881.48M | 1.63B | 2.99B | 2.44B |
| Inventory | 52.96M | 78.61M | 95.40M | 1.07B | 714.06M | 597.04M | 480.45M | 416.96M |
| Total assets | 5.20B | 5.54B | 6.54B | 12.30B | 10.84B | 11.39B | 12.01B | 11.66B |
| Total current liabilities | 345.49M | 364.49M | 653.75M | 809.30M | 933.19M | 1.54B | 1.04B | 2.24B |
| Short-term debt | 33.39M | 46.12M | 260.78M | 46.76M | 46.94M | 624.40M | 45.78M | 1.04B |
| Long-term debt | 1.56B | 1.57B | 1.85B | 6.02B | 5.69B | 5.11B | 6.08B | 4.33B |
| Total liabilities | 2,446,069,000.00 | 2,427,916,000.00 | 2,876,156,000.00 | 8,333,448,000.00 | 7,749,521,000.00 | 7,656,362,000.00 | 7,918,501,000.00 | 7,340,756,000.00 |
| Total equity | 2.76B | 3.11B | 3.66B | 3.97B | 3.09B | 3.74B | 4.09B | 4.32B |
| Retained earnings | 841.05M | 1.07B | 1.16B | 830.23M | 733.59M | 878.66M | 1.13B | 646.18M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 4.13B | 3.35B | 3.76B | 4.17B | 4.58B | 3.97B |
| Cash & ST investments | 2.57B | 1.67B | 2.05B | 2.44B | 2.87B | 2.20B |
| Inventory | 492.78M | 504.99M | 483.11M | 416.96M | 437.50M | 443.00M |
| Total assets | 11.53B | 10.94B | 11.36B | 11.66B | 11.86B | 11.08B |
| Total current liabilities | 1.22B | 2.07B | 2.27B | 2.24B | 2.25B | 2.23B |
| Short-term debt | 44.44M | 1.04B | 1.04B | 1.04B | 1.05B | 1.03B |
| Long-term debt | 5.34B | 4.34B | 4.33B | 4.33B | 4.32B | 3.34B |
| Total liabilities | 7,359,791,000.00 | 7,237,782,000.00 | 7,397,455,000.00 | 7,340,756,000.00 | 7,327,300,000.00 | 6,279,200,000.00 |
| Total equity | 4.17B | 3.71B | 3.96B | 4.32B | 4.53B | 4.80B |
| Retained earnings | 1.03B | 191.31M | 442.73M | 646.18M | 939.20M | 1.13B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 798.90M | 776.40M | 899.65M | 778.51M | 1.27B | 1.09B | 1.40B | 1.36B |
| Depreciation & amortization | 216.73M | 370.16M | 278.25M | 552.48M | 629.47M | 638.70M | 660.07M | 696.30M |
| Free cash flow | 667.43M | 594.07M | 520.39M | 732.98M | 773.78M | 1.05B | 1.35B | 1.15B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -523.67M | -301.45M | -146.54M | 0 | -54.00K | -269.76M | -311.43M | -125.02M |
| Ending cash balance | 309.62M | 637.34M | 1.06B | 591.45M | 881.48M | 1.51B | 2.41B | 1.39B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 429.80M | 88.80M | 474.66M | 362.52M | 408.20M | 415.70M |
| Depreciation & amortization | 164.80M | 174.00M | 178.33M | 179.17M | 181.40M | 179.10M |
| Free cash flow | 390.90M | 75.90M | 386.93M | 292.29M | 388.50M | 243.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -23.00K | 0 | -- | -- |
| Ending cash balance | 1.86B | 1.19B | 1.33B | 1.39B | 1.84B | 1.62B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 16.35 | 17.84 | 7.05 | -8.65 | -6.36 | 12.16 | 14.31 | -8.47 |
| ROA %i | 8.66 | 9.74 | 3.95 | -3.50 | -1.94 | 3.73 | 4.79 | -3.01 |
| ROIC %i | 11.85 | 12.48 | 6.04 | -1.57 | -0.11 | 6.83 | 7.45 | -2.11 |
| 5-year avg ROE %i | 17.40 | 20.09 | 17.06 | 10.77 | 5.25 | 4.41 | 3.70 | 0.60 |
| EBIT margin %i | 32.08 | 24.36 | 15.86 | 5.36 | -2.31 | 15.32 | 17.41 | -10.14 |
| FCF / sales %i | 35.30 | 27.48 | 22.02 | 23.69 | 21.15 | 27.36 | 33.13 | 26.85 |
| Current ratioi | 3.57 | 4.47 | 4.34 | 3.23 | 2.79 | 2.24 | 4.46 | 1.86 |
| Quick ratioi | 3.15 | 3.93 | 3.87 | 1.43 | 1.64 | 1.52 | 3.57 | 1.46 |
| Debt / assetsi | 30.68 | 31.98 | 34.42 | 50.03 | 53.64 | 50.83 | 51.30 | 46.52 |
| LT debt / equityi | 56.68 | 55.45 | 54.34 | 153.99 | 186.83 | 138.27 | 149.41 | 101.40 |
| Interest coveragei | 7.87 | 7.29 | 3.76 | 0.60 | -0.29 | 2.03 | 2.98 | -2.22 |
| Revenue CAGR (3Y) %i | 12.59 | 13.26 | 13.45 | 17.84 | 19.18 | 17.50 | 9.56 | 5.26 |
| Net income CAGR (3Y) %i | 10.71 | 9.66 | -21.21 | -- | -- | 20.24 | -- | -- |
| FCF CAGR (3Y) %i | 10.40 | 13.25 | -3.50 | 3.17 | 9.21 | 26.32 | 22.51 | 13.99 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.25 | -10.84 | -9.06 | -8.47 | 0.68 | 22.11 |
| ROA %i | 4.22 | -3.63 | -3.12 | -3.01 | 0.25 | 8.54 |
| ROIC %i | 6.82 | -2.55 | -2.22 | -2.11 | 1.41 | 11.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.46 | -7.35 | -12.08 | -10.14 | -0.85 | 19.53 |
| FCF / sales %i | 36.62 | 30.34 | 29.80 | 26.85 | 25.76 | 28.49 |
| Current ratioi | 3.38 | 1.62 | 1.65 | 1.86 | 2.04 | 1.78 |
| Quick ratioi | 2.64 | 1.15 | 1.24 | 1.46 | 1.65 | 1.38 |
| Debt / assetsi | 46.99 | 49.64 | 47.80 | 46.52 | 45.68 | 39.79 |
| LT debt / equityi | 128.75 | 118.46 | 110.77 | 101.40 | 96.45 | 70.36 |
| Interest coveragei | 2.60 | -1.42 | -2.50 | -2.22 | -0.21 | 5.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Identification, development and commercialization of meaningful pharmaceutical products that address100.00%
Quote time 2026-10-08 04:15:57 · For reference only, not investment advice and not tailored to your situation.